90% of my anxiety is gone.

90% of my anxiety is gone.

Wanted to share my experiment:

Started taking 50-100 mg of CDB oil a day along with 200-400 mg of L-Theanine a day about a week ago. I also decreased my THC intake and started vaping 1:1 THC to CDB oil being sure that the THC strain was indica dominant. Note that I used to take dabs daily at 80-90% THC and it started causing paranoia.

I was done with it.

I will admit that 100 mg of CDB with 400 mg of L-Theanine is a bit much for me. Was basically couch locked. But after a few days I found my sweet spot at 50 mg CBD and 200 mg of L-Theanine. As of now my heart rate is down. My blood pressure is 50% decreased and although my body is a little heavy (lol) I’m CALMER.

To anyone trying to avoid Xanax or other meds with heavy side effects I think the above combo is worth a shot. Maybe doesn’t work for everyone but my anxiety is definitely at bay.

submitted by /u/Blackhat323 to r/CBD
[link] [comments] #CBD #Hemp https://www.reddit.com/r/CBD/comments/idh3tf/90_of_my_anxiety_is_gone/ August 20, 2020 7:32 pm

Copyright 1994-2023 Richard Rose, all rights reserved. Any views expressed herein are the personal opinion of Richard Rose. This is a noncommercial public service. There are no warranties whatsoever as to the legality, suitability, ownership, purpose, or accuracy of this information. I am not a doctor or a lawyer. If you have medical questions, please seek a medical professional. If you have legal questions, please seek a legal professional. Information found here is not intended to diagnose, cure, treat, or prevent any disease. These statements and subsequent links found here have not been evaluated by the U.S. Food and Drug Administration (FDA). Hemp is not subject to international drug controls and is grown legally around the world. The information posted here is for educational purposes only and is not to be considered legal or medical advice, and is not intended to replace consultation with a qualified legal or medical professional. This website uses cookies. By continuing to use this service, you agree to their use. This is provided on an “as is,” “as available” basis without warranties of any kind, express or implied. The user assumes all responsibility and risk for the use of this website. Links are provided only as an informational resource, and it should not be implied that we own, recommend, endorse or approve of any of the content at the linked sites, nor are we responsible for their content. Unless otherwise stated, nobody pays us nuttin’ to post content, and we have no sponsors unlike NASCAR. By providing your email address to us you agree to be on the free The Richard Rose Report mailing list; you may unsubscribe at any time. There is no charge. To learn more about how we collect, keep, and process your private information in compliance with GDPR, please view our privacy policy via a link at the bottom of this page. Void where prohibited. Specifications subject to change without notice. If you don’t agree with the above please leave immediately. “HempNut,” “The Hemp Nut,” “Hempeh,” “HempRella,” “Not-Pot,” “Nobacco,” “CannaSearch,” “CannaSearch Daily,” “CannaSearch Breaking News,” “The HempNut Cookbook,” “The Richard Rose Report,” “Medicinal Hemp Association,” “Hemp Flower Products Association,” “CannLib,” “CannLib Search,” and the rest of my intellectual property are trademarks, service marks, and/or copyrights of Richard Rose, all rights reserved. All patents, service marks, trademarks, and copyrights are the property of their respective owners. To the best of my knowledge, all Articles, Downloads, and Posts authored by RR are absolutely not written with any type of AI, just a human brain. Grammarly and autocorrect might be used to make minor edits. Posts authored under CannaSearch Daily are written by the original external poster, and no claim is made for those. It’s obvious that GPT language models will be deployed everywhere, but their accuracy is still low so I avoid them for now. Plus writers write.

Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration December 9, 2023
Alzheimer's disease (AD) is a leading neurodegenerative condition causing cognitive and memory decline. With small-molecule drugs targeting Aβ proving ineffective, alternative targets are urgently needed. Neuroinflammation, which is central to AD's pathology, results in synaptic and neuronal damage, highlighting the importance of addressing inflammation and conserving neuronal integrity. Cannabidiol (CBD), derived from cannabis, is noted […]
Cannabis as a Source of Approved Drugs: A New Look at an Old Problem December 9, 2023
Cannabis plants have been used in medicine since ancient times. They are well known for their anti-diabetic, anti-inflammatory, neuroprotective, anti-cancer, anti-oxidative, anti-microbial, anti-viral, and anti-fungal activities. A growing body of evidence indicates that targeting the endocannabinoid system and various other receptors with cannabinoid compounds holds great promise for addressing multiple medical conditions. There are two […]
Estimation of In Vitro True Digestibility and Fiber Degradation from Feedstuff Fiber Composition When Incubated in Equine Fecal Inoculum December 9, 2023
Neutral detergent fiber (NDF) and acid detergent fiber (ADF) composition have been shown to predict in vitro true digestibility (IVTD), in vitro NDF digestibility (IVNDFD), and in vitro ADF digestibility (IVADFD) in ruminants. This study's objective was to estimate in vitro digestibility measures within the Daisy^(II) incubator using equine fecal inoculum from feedstuff NDF and […]
In Vitro Evidence of Selective Pro-Apoptotic Action of the Pure Cannabidiol and Cannabidiol-Rich Extract December 9, 2023
Plant cannabinoids, secondary metabolites of species belonging to the Cannabis genus, can mimic the endocannabinoids' action and exert biological effects. Considering the contribution of the endocannabinoid system in cell cycle and apoptotic regulation, there is an interest in exploring the potential anti-cancer activities of natural and synthetic cannabinoids. Cannabidiol (CBD), an abundant plant cannabinoid, reveals […]
In Vitro and In Vivo Anti-Inflammatory Potential of Cannabichromene Isolated from Hemp December 9, 2023
Cannabichromene (CBC), a non-psychoactive cannabinoid found in Cannabis sativa, has recently been shown to possess several medicinal properties. However, how CBC produces anti-inflammatory effects and the mechanisms of this remain poorly studied. Therefore, we extracted and purified the CBC from the Cannabis sativa cv. pink pepper (hemp cultivar). The efficacy of CBC in reducing inflammation […]
Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells December 9, 2023
Cannabidiol (CBD) is a chemical obtained from Cannabis sativa; it has therapeutic effects on anxiety and cognition and anti-inflammatory properties. Although pharmacological applications of CBD in many types of tumors have recently been reported, the mechanism of action of CBD is not yet fully understood. In this study, we perform an mRNA-seq analysis to identify […]
Hepatotoxicity due to dietary supplements: state-of-the-art, gaps and perspectives December 8, 2023
Food supplements are products intended to complement the normal diet and consist of concentrated sources of nutrients or other substances with a nutritional or physiological effect. Although they are generally considered safe if the manufacturer's recommendations are followed, many of them have shown hepatotoxic properties. This can cause many diseases (e.g. steatohepatitis and cirrhosis) characterized […]
Pharmacological Characterization of the Endocannabinoid Sensor GRAB<sub>eCB2.0</sub> December 8, 2023
Introduction: The endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and arachidonoyl ethanolamine (AEA), are produced by separate enzymatic pathways, activate cannabinoid (CB) receptors with distinct pharmacological profiles, and differentially regulate pathophysiological processes. The genetically encoded sensor, GRAB(eCB2.0), detects real-time changes in eCB levels in cells in culture and preclinical model systems; however, its activation by eCB analogues produced […]
Enhancing transmucosal delivery of CBD through nanoemulsion: in vitro and in vivo studies December 8, 2023
Cannabidiol (CBD) has gained significant attention as a complementary and alternative medicine due to its promising therapeutic properties. However, CBD faces obstacles when administered orally due to its poor solubility in water, leading to limited absorption into the bloodstream and low and variable bioavailability. Therefore, the development of innovative delivery approaches that can enhance CBD's […]
THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation December 8, 2023
Prenatal infections and cannabis use during adolescence are well-recognized risk factors for schizophrenia. As inflammation and oxidative stress (OS) contribute to this disorder, anti-inflammatory drugs have been proposed as potential therapies. This study aimed to evaluate the association between delta-9-tetrahydrocannabinol (THC) and schizophrenia-like abnormalities in a maternal immune activation (MIA) model. Additionally, we assessed the […]
An observational study of clinical outcome measures in patients treated with cannabis-based medicinal products on the UK Medical Cannabis Registry December 7, 2023
CONCLUSION: There was an associated improvement in self-reported anxiety, sleep quality, and HRQoL in patients treated with the CBMPs. Those prescribed treatment formulations including dried flower were most likely to show a clinical improvement. However, these results must be interpreted with caution given the limitations of study design.
UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention-deficit/hyperactivity disorder December 7, 2023
CONCLUSION: An association between CBMP treatment and improvements in anxiety, sleep quality, and general HRQoL was observed in patients with ADHD. Treatment was well tolerated at 12 months. Results must be interpreted with caution as a causative effect cannot be proven. These results, however, do provide additional support for future evaluation within randomized controlled trials.
Cannabidiol Inhibits IgE-Mediated Mast Cell Degranulation and Anaphylaxis in Mice December 7, 2023
CONCLUSION: Based on these results, the administration of CBD is a new therapeutic intervention in mast cell-associated anaphylactic diseases.
Herbal Supplement Use Among Adolescent and Young Adult Women in a Family Planning Clinic December 7, 2023
CONCLUSION: Adolescent and young adult women frequently reported past and current herbal medicine and supplement use, with high rates of moderate risk supplement-drug interactions. Further research is needed to better elucidate these clinically-relevant supplement-contraception interactions.
Multi targets of cannabidiol (CBD) on skeletal mammalian and avian neuromuscular preparations December 6, 2023
Cannabidiol (CBD) has been used in diseases that affect the central nervous system. Its effects on the peripheral synapses are of great interest, since endocannabinoid receptors are expressed in muscles. CBD (0.3 mM) was analysed using mammalian and avian neuromuscular preparations, through myographic techniques in complementary protocols. Mammalian cells were examined by light microscopy while […]
Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial December 6, 2023
Information on the pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered cannabis-based medicine (CBM) in capsule formulation in patient populations is sparse. In this exploratory study, we aimed to evaluate the PK and PD in a probable steady state of CBM in neuropathic pain and spasticity in a population of patients with multiple sclerosis (MS). […]
Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol December 6, 2023
No abstract
Cannabidiol represses miR-143 to promote cardiomyocyte proliferation and heart regeneration after myocardial infarction December 5, 2023
Mammalian heart is capable to regenerate almost completely early after birth through endogenous cardiomyocyte proliferation. However, this regenerative capacity diminishes gradually with growth and is nearly lost in adulthood. Cannabidiol (CBD) is a major component of cannabis and has various biological activities to regulate oxidative stress, fibrosis, inflammation, and cell death. The present study was […]
Factors influencing the in situ formation of Δ9-THC from cannabidiol during GC-MS analysis December 5, 2023
Gas chromatography-mass spectrometry (GC-MS) is widely used for the identification of cannabinoids in seized plant material. Conditions used for instrumental analysis should maximize decarboxylation, while minimizing the in situ production of Δ9-THC inside the GC inlet. In this study, decarboxylation of the acidic Δ9-THC precursor and in situ degradation of cannabidiol (CBD) were investigated using […]
Exploring the Antibacterial Potential of Semisynthetic Phytocannabinoid: Tetrahydrocannabidiol (THCBD) as a Potential Antibacterial Agent against Sensitive and Resistant Strains of <em>Staphylococcus aureus</em> December 5, 2023
Antimicrobial resistance (AMR) is one of the most challenging problems and is responsible for millions of deaths every year. We therefore urgently require new chemical entities with novel mechanisms of action. Phytocannabinoids have been adequately reported for the antimicrobial effect but not seriously pursued because of either stringent regulatory issues or poor drug-like properties. In […]